QUOTE AND NEWS
MarketWatch  May 22  Comment 
Wall Street has gone from worrying the economy is not strong enough to thinking it might be too strong. Here’s why.
newratings.com  May 4  Comment 
WASHINGTON (dpa-AFX) - The Centers for Disease Control and Prevention (CDC) urged healthcare providers in the United States to refer parents of young children with attention-deficit/hyperactivity disorder (ADHD) for training in behavior therapy...
Forbes  Feb 12  Comment 
When Taylor Ferguson started as a freshman at Towson University in Baltimore, she was already well ahead of her nursing program classmates. As a high school student in the Academy of Health Professions Program at Western School of Technology and...
Benzinga  Feb 12  Comment 
Apple Inc. (NASDAQ: AAPL) is backing a "top-secret" scripted series starring Dr. Dre, according to a report by The Hollywood Reporter. HR, citing "multiple sources," stated that Dr. Dre will also serve as an executive producer in Apple's...
Reuters  Feb 8  Comment 
A doctor at a hospital in India's capital, New Delhi, was recently tracking a wall of monitors displaying the vital signs of intensive care patients admitted hundreds of miles away when red-and-yellow alerts rang out.




 
TOP CONTRIBUTORS

Headquartered in Totowa, New Jersey, Vital Signs (VITL) is a leading designer, manufacturer, and marketer of airway management products for the anesthesia, respiratory/critical care, and sleep disorder markets. The company sells its products in more than 70 countries globally. The company provides the broadest single-patient use anesthesia and respiratory/critical care product lines in the industry. Beginning in 1997 with the equity interest in Breas Medical AB, the company has expanded its focus to the sleep therapy and personal ventilation markets. It also delivers technology services to FDA regulated companies. The company derives revenues principally from five segments: Anesthesia, Respiratory/Critical Care, Sleep Disorder, Pharmaceutical Technology Services, and Interventional Cardiology/Radiology. The Pharmaceutical Technology Services segment was classified, as of FQ107, as a discontinued operation, with VITL expecting the unit to be sold. However, as of FQ407, the segment has been reclassified to continuing operations since the company received no acceptable offers for sale. The Interventional Cardiology/Radiology business operates primarily as Thomas Medical. It was earlier included in the anesthesia segment, but is now segregated. The company has been operating in the Anesthesia market for 33 years and provides single-patient use anesthesia breathing circuits, face masks, and general anesthesia products. These products comprise air-filled cushion face masks, breathing circuits and temperature monitoring probes, single limb breathing circuits, single use airway devices, and fiberoptic laryngoscope systems. The Respiratory/Critical Care segment provides arterial blood gas syringes and kits, manual resuscitators, and blood pressure cuffs. The company also distributes critical care equipment kits and modules, which are color coded to allow emergency room workers to quickly and accurately determine the proper equipment size to use with pediatric patients. The Sleep Disorder segment offers sleep disorder/personal ventilation products that include continuous positive airway pressure flow generators, humidification systems, sleep disorder home screening devices, life support ventilator, and other ventilators. This segment also provides diagnostic and therapeutic services for sleep disorders. The Pharmaceutical Technology Services segment offers consulting services to medical device, diagnostic, and biotechnology companies, thereby helping the companies to develop and validate systems and processes for their manufacturing, infrastructure, research and development, and laboratory and quality assurance departments. In fiscal 2007 (fiscal year ends September) Anesthesia, Respiratory/Critical Care, Sleep Disorder, Pharmaceutical Technology Services, and Interventional Cardiology/Radiology contributed 36%, 23%, 21%, 6%, and 14% of revenues, respectively.




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki